DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/bvnrbc/rna_mirna_rnai_a) has announced the addition of the "RNA (Mirna, Rnai & Sirna) Therapy in Oncology Drug Pipeline Update 2012" report to their offering.

Potentially any disease-causing gene, cell type or tissue can be targeted with miRNA, RNAi or siRNA, including those not 'druggable' with small molecules or protein-based therapies.

There are today 49 companies plus partners developing 69 RNA (miRNA, RNAi & siRNA) drugs in 91 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 24 drugs. Rna (Mirna, Rnai & Sirna) Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 49 different targets. These targets are further categorized on in the software application by 23 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.

How May Drug Pipeline Update Be of Use?

- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

- Find competitors, collaborations partners, M&A candidates etc.

- Jump start competitive drug intelligence operations

- Excellent starting point for world wide benchmarking

- Compare portfolio and therapy focus with your peers

Read more here:
Research and Markets: RNA (Mirna, Rnai & Sirna) Therapy in Oncology Drug Pipeline Update 2012

Comments are closed.